However, it is reasonable to conclude the optimal dose of a D1R agonists for improving cognitive function in a disease state may vary according to individual differences and neuropsychiatric conditions and also suggest that dopaminergic treatments of psychiatric disorders should consider baseline DA levels in order to avoid side effects of over-or underdosing on cognition (Floresco, 2013). This evidence concerns the gene DRD1 and psychiatric disorder.